Developed under the auspices of the University of Glasgow supported by unrestricted educational grants from Pfizer Italia S.r.l. and R-Pharm CJSC
The use of cytokine inhibitors as a treatment for inflammatory diseases is at the forefront of scientific development and is beginning to move from clinical trials into practice. With the approval of tofacitinib in many countries and other agents moving into phase II/III trials, staying current with the ongoing research is critical to clinical practice. The development of these agents brings in new targeted therapy and has the potential of great benefit to patients. This course outlines recent developments in cytokine signalling and IL-6 inhibition and show how these developments may come to clinical fruition over the coming years.
By following this programme, you will be able to:
Professor Leonard Calabrese
Director & Professor of Medicine,
Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.
He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation.
He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles.
|Emerging cytokine signalling agents - where are we in 2015?||
Professor Roy Fleischmann
Clinical Professor of Medicine,
Dr. Fleischmann is a Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and in private practice at Rheumatology Associates, Dallas, Texas. He has served as Chief of the Division of Rheumatology at UTSMC-University Hospitals-St. Paul, Dallas, Texas since 1978. Dr. Fleishmann is Co-Medical Director of Metroplex Clinical Research Center.
He received his Doctor of Medicine (M.D.) from the State University of New York, Downstate Medical Center in 1969, before completing his residency in Internal Medicine at the Mt Sinai Hospital, New York City, New York, and his Fellowship in Rheumatology at the College of Physicians and Surgeons, Columbia University, New York City, New York.
|Tofacitinib: clinical data update||
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR),
Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe.
Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies
His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine.
|The emerging safety profile of JAK inhibitors||
Professor Kevin Winthrop
Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology,
Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases.
Date of preparation: December 2015